|
|
|
|
|
|
Sponsored by: |
Intercell USA, Inc. |
Information provided by: | Intercell USA, Inc. |
ClinicalTrials.gov Identifier: | NCT00751777 |
To evaluate and compare the immune responses and safety following a two vaccination regimen by transcutaneous immunization with heat-labile enterotoxin of E. coli (LT) patches or placebo patches.
Condition | Intervention | Phase |
Prevention of Travelers' Diarrhea |
Biological: heat-labile enterotoxin of E. coli (LT) Biological: Placebo |
Phase II |
MedlinePlus related topics: | Diarrhea |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Two Vaccination Regimen With an LT Vaccine Patch in Healthy Adults |
Estimated Enrollment: | 120 |
Study Start Date: | September 2008 |
Estimated Study Completion Date: | November 2009 |
Estimated Primary Completion Date: | October 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Experimental
80 subjects will receive a two vaccination regimen with a LT patch.
|
Biological: heat-labile enterotoxin of E. coli (LT)
Travelers' Diarrhea Vaccine System
|
2: Placebo Comparator
40 subjects will receive a two vaccination regimen with a placebo patch.
|
Biological: Placebo
Travelers' Diarrhea Vaccine System
|
Ages Eligible for Study: | 18 Years to 64 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |||||
Solano Clinical Research | Recruiting | ||||
Vallejo, California, United States, 94589 | |||||
Contact: Brenda Grooms 707-556-1107 ext 230 bgrooms@solanoclinicalresearch.com | |||||
Principal Investigator: Peter Rogge, MD | |||||
United States, Florida | |||||
Miami Research Associates | Recruiting | ||||
South Miami, Florida, United States, 33143 | |||||
Contact: Maria Heimer 305-279-0015 ext 4231 mheimer@miamiresearch .com | |||||
Principal Investigator: Eric Sheldon, MD | |||||
United States, Ohio | |||||
Radiant Research, Cincinnati | Recruiting | ||||
Cincinnati, Ohio, United States, 45249 | |||||
Contact: Nancy Cipollone 513-247-5590 nancycipollone@radiantresearch.com | |||||
Principal Investigator: Michael Noss, MD | |||||
United States, Texas | |||||
Clinical Trials of Texas | Recruiting | ||||
San Antonio, Texas, United States, 78229 | |||||
Contact: Kay Scroggins 210-949-0122 kscroggins@cttexas.com | |||||
Principal Investigator: Elizabeth Tichy, MD |
Intercell USA, Inc. |
Principal Investigator: | Eric Sheldon, MD | Miami Research Associates |
Responsible Party: | Intercell USA, Inc. ( Sarah Frech, Clinical Development Head ) |
Study ID Numbers: | ELT207 |
First Received: | September 11, 2008 |
Last Updated: | September 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00751777 |
Health Authority: | United States: Food and Drug Administration |
|